Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
May 18 2022 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company seeking to develop innovative proprietary
medicines in areas of significant unmet medical need in oncology
and infectious disease with a current focus on breast cancer and
COVID-19, today announces that Kyle Guse, Chief Financial Officer
and General Counsel, will present a corporate overview at the H.C.
Wainwright Global Hybrid Investment Conference. The conference is
being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami
Beach, FL.
Presentation Date: |
May 24, 2022 |
|
|
Time: |
12:30pm ET |
Mr. Guse will be available for one-on-one meetings. To request a
meeting and to register for the conference, click here:
In-Person
Virtual
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to develop innovative proprietary medicines in
areas of significant unmet medical need in oncology and infectious
diseases with a current focus on breast cancer and COVID-19. For
more information, please
visit www.atossatherapeutics.com.
FORWARD-LOOKING STATEMENTS DISCLAIMER
STATEMENT
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including,
without limitation, statements regarding the satisfaction of
closing conditions relating to the offering and the anticipated use
of proceeds from the offering, the risks and uncertainties
associated with any variation between interim and final clinical
results, actions and inactions by the FDA, the outcome or timing of
regulatory approvals needed by Atossa including those needed to
commence and continue studies of AT-H201, AT-301 and Endoxifen,
lower than anticipated rate of patient enrollment, estimated market
size of drugs under development, the safety and efficacy of
Atossa’s products, performance of clinical research organizations
and investigators, obstacles resulting from proprietary rights held
by others such as patent rights, whether reduction in Ki-67 or any
other result from a neoadjuvant study or reduction of breast
density will be approvable endpoints for oral Endoxifen, and other
risks detailed from time to time in Atossa’s filings with the
Securities and Exchange Commission, including without limitation
its periodic reports on Form 10-K and 10-Q, each as amended and
supplemented from time to time.
COMPANY CONTACT:Atossa Therapeutics, Inc. Kyle
Guse, CFO and General Counsel Office: (866) 893-4927
kyle.guse@atossainc.com
INVESTOR RELATIONS CONTACT: Core IR Office:
(516) 222-2560 ir@atossainc.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024